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ABSTRACT
The mitotic spindle assembly checkpoint (SAC) is an essential control system of 
the cell cycle that contributes to mantain the genomic stability of eukaryotic cells. 
SAC genes expression is often deregulated in cancer cells, leading to checkpoint 
impairment and chromosome instability. The mechanisms responsible for the 
transcriptional regulation and deregulation of these genes are still largely unknown. 
Herein we identify the nonhistone architectural nuclear proteins High Mobility Group 
A1 (HMGA1), whose overexpression is a feature of several human malignancies 
and has a key role in cancer progression, as transcriptional regulators of SAC genes 
expression. In particular, we show that HMGA1 proteins are able to increase the 
expression of the SAC genes Ttk, Mad2l1, Bub1 and Bub1b, binding to their promoter 
regions. Consistently, HMGA1-depletion induces SAC genes downregulation associated 
to several mitotic defects. In particular, we observed a high number of unaligned 
chromosomes in metaphase, a reduction of prometaphase time, a delay of anaphase, 
a higher cytokinesis time and a higher percentage of cytokinesis failure by using live-
cell microscopy. Finally, a significant direct correlation between HMGA1 and SAC genes 
expression was detected in human colon carcinomas indicating a novel mechanism 
by which HMGA1 contributes to cancer progression.
INTRODUCTION
The High Mobility Group A (HMGA) protein 
family is comprised of three proteins: HMGA1a and 
HMGA1b, which are encoded by the HMGA1 gene 
through alternative splicing [1], and the related HMGA2 
protein, encoded by a distinct gene [2]. These proteins are 
nonhistone architectural nuclear factors, able to bind the 
minor groove of AT-rich DNA sequences through three 
“AT-hook” domains. The involvement of HMGA proteins 
in embryogenesis, cell proliferation, differentiation, 
apoptosis and, above all, cancer development has been 
extensively demonstrated [3]. In particular, HMGA 
proteins seem to play their major physiologic role during 
embryonic development where they are abundantly 
expressed, whereas their expression is low or negligible 
in normal adult tissues [4, 5]. Conversely, HMGA 
overexpression is a feature of malignant neoplasias 
[3], where it represents a poor prognostic index, as it 
often correlates with a reduced survival [6]. It has been 
previously demonstrated that HMGA proteins have 
oncogenic activity since their overexpression leads to the 
transformation of rat fibroblasts [7] and human epithelial 
breast cells [8], and transgenic mice overexpressing the 
HMGA proteins develop multiple neoplasias [9–13].
The mechanisms accounting for cell transformation 
induced by the HMGA proteins are essentially based on 
their ability to activate or inhibit the expression of genes 
involved in the control of cellular proliferation, invasion 
and apoptosis [3, 14–16].
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A hallmark of human cancer is genome instability, 
whose prominent form is represented by chromosomal 
instability (CIN). This can consist in gain or loss of 
whole chromosomes, translocation/deletion/duplication 
of chromosome segments or polyploidy. Alterations in 
chromosome number or aneuploidy are found in nearly all 
major human tumor types [17], generally associated with 
the most aggressive forms of cancer. Alterations of the 
genes coding for proteins involved in Spindle Assembly 
Checkpoint (SAC), frequently observed in human malignant 
neoplasias, account for aneuploidy of cancer cells [18]. 
However, mutations in SAC genes are quite rare in human 
cancers (reviewed in [19]), whereas their deregulation is 
more frequent. Indeed, downregulation of Bub1 expression 
has been detected in a subset of acute myeloid leukemia 
[20], whereas upregulation of Bub1 levels has been reported 
in lymphomas [21], breast [22] and gastric cancers [23, 24]. 
Therefore, these studies demonstrate that both upregulation 
and downregulation of SAC genes can cause a checkpoint 
impairment leading to CIN.
Since HMGA expression is associated with a 
highly malignant phenotype that is characterized by 
CIN which accelerates tumor progression leading to a 
higher malignant state, the aim of this work has been to 
investigate whether HMGA1 proteins are able to regulate 
the expression of SAC genes, and, thereby, evaluate 
HMGA1 role in CIN.
Herein we report that HMGA1 increases the 
transcription of Bub1, Bub1b, Mad2l1 and Mps1/Ttk 
genes involved in the SAC. We have found that HMGA1 
knock-down compromises the mitotic checkpoint activity, 
and consistently HMGA1-depleted cells show a higher 
percentage of metaphases with unaligned chromosomes 
and a reduced prometaphase time compared to control 
cells, indicating a SAC impairment. Finally, human 
colon carcinomas show high SAC gene expression that 
correlates with HMGA1 protein levels.
RESULTS
HMGA1 increases the transcription of Bub1, 
Bub1b, Mad2l1 and Ttk genes involved in 
the SAC
In order to identify a possible role of HMGA1 
in the induction of chromosomal instability we have 
investigated, first, the ability of HMGA1 to regulate the 
expression of SAC genes, focusing our attention on Bub1, 
Bub1b, Mad2l1 and Ttk genes.
These genes have been chosen because their 
promoters contain AT-rich regions, which represent 
putative binding sites for HMGA1 proteins, flanking 
the consensus binding sites for the same transcription 
factors (Supplementary Figure S1), some of which 
have been described as interactors of HMGA1 proteins 
(Supplementary Figure S1).
Therefore, we have evaluated the expression 
of Bub1, Bub1b, Mad2l1 and Ttk at mRNA level by 
quantitative PCR (qPCR) in mouse NIH3T3 cells 
transfected with the pCEFL-HA-Hmga1b expression 
vector encoding HMGA1b. As shown in Figure 1A, the 
expression of Bub1, Bub1b, Mad2l1 and Ttk genes is 
higher in the cells overexpressing HMGA1 in comparison 
with the empty vector-transfected NIH3T3 cells (CV). 
Parallel results were obtained when total cellular extracts 
from the same cells were analyzed by western blotting 
with the antibodies raised against BUBR1 and MAD2 
proteins (Figure 1B). Moreover, the same results have 
been obtained in human colorectal HCT116, SW620 and 
SW48 cells overexpressing or not the HMGA1b protein 
(Figure 1C and 1D, and Supplementary Figure S2).
These results suggest a role of the HMGA1b protein 
in the activation of SAC gene expression.
HMGA1 binds Bub1, Bub1b, Mad2l1 and Ttk 
promoters in vivo
As described above, Bub1, Bub1b, Mad2l1 and Ttk 
promoter regions contain some AT-rich DNA sequences 
which are the preferred binding sites for HMGA1 proteins. 
Therefore, we analyzed the ability of the HMGA1 proteins 
to bind the promoter regions of these genes by chromatin 
immunoprecipitation (ChIP) assays. Thus, HCT116 cells 
were cross-linked with formaldehyde, and DNA-chromatin 
complexes were subjected to immunoprecipitation with 
anti-HMGA1 or anti-IgG antibodies used as control. The 
recovered DNA was subsequently analyzed by qPCR, 
using primers spanning specific AT-rich regions of the 
indicated promoters. Specifically, the following AT-
rich regions of these promoters: -760/-567 region of the 
Bub1 promoter, -740/-550 region of the Bub1b promoter, 
-442/-198 region of the Mad2l1 promoter, and -380/-194 
region of the Ttk promoter, containing putative binding 
sites for HMGA1 proteins (see Supplementary Figure S1), 
were analyzed. The immunoprecipitated DNA has also 
been amplified using primers for the glyceraldehyde 
3-phosphate dehydrogenase (Gapdh) gene promoter as 
negative control. As shown in Figure 2A, occupancy of 
Bub1, Bub1b, Mad2l1 and Ttk promoters by HMGA1 has 
been detected in the anti-HMGA1-precipitated chromatin 
from HCT116 cells. Conversely, no amplification was 
observed with anti-IgG precipitates and when primers for 
the Gapdh promoter were used, indicating the specificity 
of the binding of HMGA1 proteins to the Bub1, Bub1b, 
Mad2l1 and Ttk promoters.
Finally, to assess the functional consequences of 
the HMGA1 binding to these promoters, we investigated 
whether HMGA1 proteins were able to regulate these 
promoters performing luciferase activity assays in NIH3T3 
cells. To this aim, NIH3T3 cells have been co-transfected 
with a reporter vector (pGL3-Basic) carrying the firefly-
luciferase gene under the control of Bub1, Bub1b, Mad2l1 
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and Ttk promoters, with different amounts of pcDNA3.1-
Hmga1b and renilla-luciferase reporter vector (used for 
normalization). Insert-less pcDNA3.1 vector has been used 
as control (CV). As shown in Figure 2B, HMGA1 increases 
Bub1, Bub1b, Mad2l1 and Ttk promoter activities.
Taken together, these results demonstrate that 
HMGA1 is able to bind to the Bub1, Bub1b, Mad2l1 and 
Ttk promoters, and increase their transcriptional activity 
strongly supporting a critical role of HMGA1 in the 
regulation of SAC gene expression.
HMGA1 depletion impairs the mitotic checkpoint 
activity
Since the above described results indicate that 
HMGA1 is able to activate the expression of SAC genes 
acting at transcriptional level, we investigated whether 
HMGA1-induced SAC genes deregulation affects the 
mitotic checkpoint in mammalian cultured cells. To this 
aim, we used HeLa cells that have a functional SAC and 
are often used as a model for studying the checkpoint 
function. Since HeLa cells express HMGA1 protein 
at high levels, the further over-expression of HMGA1 
failed to induce a consistent up-regulation of SAC genes. 
For this reason, considering that both up-regulation and 
down-regulation of one or more SAC genes impair the 
checkpoint, we evaluated whether HMGA1-silencing by 
RNAi is able to down-regulate SAC genes expression in 
HeLa cells. To this aim we transfected HeLa cells with 
siRNA targeting the HMGA1 gene (HMGA1i cells) or 
with control siRNA (Ctli cells). As expected, we observed 
a drastic downregulation of SAC gene expression (Bub1, 
Bub1b, Mad2l1 and Ttk) at mRNA (Figure 3A) and protein 
level (Supplementary Figure S3). The analysis of mitotic 
cells by immunofluorescence showed the presence of a 
high number of unaligned chromosomes in metaphase in 
HMGA1i cells but not in the scrambled oligonucleotide 
transfected HeLa cells (Figure 3B and 3C). Subsequently, 
to evaluate the role of HMGA1 in the mitotic checkpoint 
regulation, we used live-cell microscopy to follow mitotic 
progression in individual cells. Filming of mitoses in HeLa 
HMGA1i and Ctli cells revealed several mitotic errors in 
HMGA1i cells. The most prominent phenotype was a 
reduction of pro-metaphase time, i.e. from the round-up to 
the chromosome segregation, in HMGA1i cells (t = 70.21 
± 40.35 min (n = 32) versus 154.52 ± 61.46 min in Ctli 
(n = 32); Figure 3D and 3F and Supplementary Movies S1 
and S2). We have observed that HMGA1i cells exhibited 
also an anaphase delay (t = 14.7 ± 8.89 min (n = 39) versus 
8.05 ± 5.02 min in Ctli (n = 23); Figure 3D and 3F and 
Supplementary Movies S1 and S2) and that they showed a 
slightly higher cytokinesis time (from the early telophase 
Figure 1: HMGA1 increases mitotic spindle regulator genes at both RNA and protein level. RNA and proteins extracted 
from NIH3T3 cells transiently transfected with pCEFL-HA-Hmga1b carrying the Hmga1b cDNA or the backbone vector (CV) were 
analyzed by qPCR for Bub1, Bub1b, Mad2l1 and Ttk expression A. and western blotting with the indicated antibodies B. The actin 
expression level has been used for normalization. Data are mean ± SD of a representative experiment performed in triplicate. *p < 0.05; 
**p < 0.01; ***p < 0.001, Student’s t test. C and D. RNA and proteins extracted from HCT116 cells treated as in (A) were analyzed by 
qPCR for Bub1, Bub1b, Mad2l1 and Ttk expression (C) and western blotting with the indicated antibodies (D) The actin expression level 
has been used for normalization.
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to abscission; t = 199.5 ± 83.65 min n = 30) than that of 
Ctli cells (t = 161.28 ± 38.43 min n = 24), associated to 
a higher percentage of cytokinesis failure resulting in 
binucleated cells (21% versus 12% in Ctli cells; Figure 3D 
and 3E). Moreover, we observed a higher percentage of 
death in mitosis and of metaphase failure in the HMGA1i 
than in Ctli cells (Figure 3E).
Altogether, these results suggest that the 
deregulation of SAC genes induced by HMGA1 depletion 
impairs the activity of the checkpoint.
HMGA1 expression levels directly correlate with 
the expression of genes involved in SAC
We evaluated the correlation between the expression 
of HMGA1 and of the SAC genes BUB1, BUB1B, MAD2L1 
and TTK, in global mRNA profiles of colorectal cancer 
generated by The Cancer Genome Atlas (TCGA; http://
cancergenome.nih.gov/) for 365 and 222 samples profiled 
with, respectively, RNAseq and DNA microarrays. HMGA1 
was found to be significantly correlated with each of the 
SAC genes both in RNAseq and microarray data (Pearson r 
between 0.22 and 0.38; p < 10−6 in 6 comparisons, and 
< 2*10−4 in the remaining two) (Figure 4A). We extended 
the analysis also to other SAC genes (AURKB, CENPE, 
AURKA and TPX2) obtaining the same results for two of 
them. Interestingly, the correlation further raised when the 
expression of the four SAC genes was averaged (r = 0.34 in 
RNAseq and 0.35 in array) (Figure 4A and 4B).
It is noteworthy that a stronger correlation between 
HMGA1 and SAC gene mRNA expression was found 
when liver metastases from colon carcinomas (n = 185) 
were analyzed by Illumina array (Figure 4A). In particular, 
we obtained a Pearson r > 0.62 and a p value < 10−6 for 
seven of the eight analyzed SAC genes, with a further 
increase for the averaged SAC genes expression (Pearson 
r = 0.72; p < 10−6).
Therefore, we attempted to confirm the association of 
HMGA1 expression with that of two SAC genes (BUBR1 
and TTK) at protein level by immunohistochemical analyses 
Figure 2: HMGA1 protein binds Bub1, Bub1b, Mad2l1 and Ttk promoters in vivo and increases their transcriptional 
activity. A. Soluble chromatin from HCT116 cells has been immunoprecipitated with anti-HMGA1 antibodies. Then, the DNAs have 
been amplified by qPCR using primers covering different regions of Bub1, Bub1b, Mad2l1 and Ttk promoters. GAPDH promoter and 
nonspecific IgG instead of anti-HMGA1 were used as control of the specificity of the HMGA1 binding to the indicated promoters. Data 
are mean ± SD of a representative experiment performed in triplicate. See also Supplementary Figure S1. B. Analysis of Bub1, Bub1b, 
Mad2l1 and Ttk luciferase reporter activities in NIH3T3 cells transiently transfected with empty vector (CV), or 0.25 and 0.5 μg of 
pcDNA3.1-Hmga1b expression vector. All the transfections were performed in duplicate. Data are mean ± SD of three independent 
experiments. *p < 0.05; **p < 0.01, Student’s t test. Western blotting analysis of HMGA1 protein from one representative experiment was 
shown (bottom). Actin was used to equalize protein loading.
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of paraffin-embedded tissues evaluating the expression of 
these proteins in 36 colon tissue specimens (three normal 
colon tissues and 33 colon carcinoma). The results of this 
analysis are summarized in Figure 5. Indeed, as previously 
reported [25, 26], HMGA1 expression was abundant 
in the colon carcinoma samples, whereas it was not 
detectable in normal colonic mucosa. Interestingly, a weak 
immunoreactivity was observed in normal colon mucosa 
after staining with antibodies raised versus BUBR1 and 
TTK, whereas colon carcinoma samples showed a strong 
Figure 3: HMGA1 depletion impairs the mitotic checkpoint. A. Control (Ctli) and HMGA1-depleted (HMGA1i) HeLa cells 
were tested for the expression of HMGA1 and SAC genes by qPCR. B. HeLa cells were transfected with Ctli and HMGAi siRNA as in 
A, fixed 48 hrs post transfection and stained with DAPI (blue) and anti-β-tubulin Ab (red) to identify the DNA and the mitotic spindle, 
respectively. About 150 metaphases per sample were scored for the presence of aligned chromosome. The data are represented as mean ± 
SD. Differences between Ctli and HMGA1i are statistically significant. ***p < 0.001, Student’s t-test. C. Representative immunostainings 
are shown (right). D. HeLa cells treated as in A and analyzed 48 h post transfection by time lapse video. For each case, duration of the 
different phases of the mitosis and of the cytokinesis was measured. The duration of the indicated mitotic phases is reported in box plot 
graph (Whisker diagram). ***p < 0.001, Student’s t-test. E. The percentage of cells with the indicated outcome is reported. F. Still images 
related to Supplementary Movies S1 and S2. See also Supplementary Figure S3.
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immunoreactivity that significantly correlated with HMGA1 
staining (p = 0.006 for BUBR1 and p < 0.001 for TTK). 
In fact, 55.5% and 44.4% of tumor samples with a weak 
HMGA1 staining (1+) had negative or weak staining also for 
BUBR1 and TTK respectively, whereas 61.5% and 66.7% of 
tumor samples with a strong HMGA1 immunoreactivity (3+) 
had also a strong immunoreactivity for BUBR1 and TTK, 
respectively. Representative cases of normal colon mucosa 
(a, b, c), colon carcinoma samples with a weak HMGA1 
immunoreactivity (d, e, f) and colon carcinoma samples with 
a strong HMGA1 reactivity (g, h, i) stained with antibodies 
versus BUBR1 and TTK are shown in Figure 5.
Therefore, human colon carcinoma show SAC 
gene overexpression that strongly correlates with that of 
HMGA1, likely contributing to cancer progression.
DISCUSSION
Overexpression of HMGA proteins, a general 
feature of human malignancies [3], has a critical role 
in cancer progression since it inhibits p53-dependent 
apoptosis by modulating transcription of p53 [27] and 
p53-target genes (reviewed in [14]), impairs DNA 
repair [28] and induces the epithelial-mesenchymal 
transition (EMT) [29, 8]. Consistently, HMGA protein 
expression is associated with a highly malignant 
phenotype being a marker of poor prognosis for cancer 
patients as their overexpression correlates with the 
resistance to anti-cancer therapies [28] and a reduced 
survival [6].
Also alterations in chromosome number or 
aneuploidy are a feature of highly malignant neoplasias and 
it is due to defects in the mitotic checkpoint that controls 
chromosome segregation during mitosis [17]. Alterations 
of the spindle assembly checkpoint genes levels likely 
account for aneuploidy in several human cancer (reviewed 
in [30, 31]) since mitotic checkpoint impairment and 
aneuploidy in human tumour cells are often associated 
with changes in the SAC gene-encoded protein levels [30]. 
It has also been reported that in some tumour cells these 
Figure 4: HMGA1 and SAC genes expression correlates in colorectal cancer samples and in liver metastases.  
A. Correlation between the expression of HMGA1 and of the SAC genes BUB1, BUB1B, MAD2L1, TTK, AURKB, CENPE, AURKA and 
TPX2 in global mRNA profiles of colorectal cancer and liver metastases (MTS). 365 and 222 clorectal carcinoma samples were profiled 
by The Cancer Genome Atlas (TCGA; http://cancergenome.nih.gov/) with, respectively, RNAseq and DNA microarrays. 185 liver MTS 
samples were profiled with Illumina array. B. Dot-plot depicting the correlation between HMGA1 and average SAC genes in liver MTS.
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Figure 5: HMGA1 proteins expression correlates with BUBR1 and TTK expression in colorectal cancer 
samples. Correlation between HMGA1, BUBR1 and TTK stainings in normal and neoplastic colon tissues by immunohistochemistry. 
*HMGA1, BUBR1 and TTK staining scores were: negative (N), <10% of positive cells; +, positive cells; 1+, 10–40% of positive 
cells; 2+, 41–70% of positive cells; 3+, 71–100% of positive cells. n, number of cases; %, percentage of examined cases; NA, not 
assessable; **normal control tissues. The correlation between HMGA1 and BUBR1 and between HMGA1 and TTK immunoreactivity 
are statistically significant: p = 0.006 and p < 0.001, respectively, calcuted by χ2 test. Representative images of paraffin sections analyzed 
by immunohistochemistry using anti-HMGA1, anti-BUBR1 and anti-TTK antibodies are shown. Immunostaining of normal mucosa 
negative (N) for HMGA1 a. BUBR1 b. and TTK c. are shown. Immunostaining of a well-differentiated colon carcinoma showing a 
weak immunoreactivity for HMGA1 d. BUBR1 e. and TTK f. are shown. Immunostaining of moderately differentiated colon carcinoma 
showing a strong immunoreactivity for HMGA1 g. BUBR1 h. and TTK i. are shown. Magnification is 10X.
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changes occur through altered transcriptional regulation by 
tumour suppressors or oncogene products [32, 33].
Therefore, in order to investigate the mechanisms 
accounting for the association of HMGA1 overexpression 
and chromosome instability, we have analyzed the ability 
of the HMGA1 proteins to transcriptionally regulate the 
genes involved in SAC.
Here, we report that HMGA1 proteins are able to 
activate the expression of the SAC genes Ttk, Mad2l1, 
Bub1 and Bub1b binding to their promoter regions. 
Consistently, HMGA1i-interfered HeLa cells (HMGA1i) 
show downregulation of these genes, whereas HMGA1-
overexpression in several human colon cancer and NIH3T3 
cells induces their upregulation. Moreover, the analysis of 
mitotic cells by immunofluorescence showed the presence 
of a high number of unaligned chromosomes in metaphase 
in HMGA1i cells associated to a reduction of prometaphase 
time. This alteration suggests that the HMGA1i cells start 
the anaphase without waiting for the proper chromosome 
alignment due to SAC impairment. Interestingly, the 
HMGA1-interfered HeLa cells resemble the cells in which the 
SAC gene Bub1b was depleted [34], indicating that HMGA1 
depletion affects the mitotic checkpoint in cultured cells.
Notably, we have found a strong correlation between 
HMGA1 and BUBR1 and TTK protein levels in human 
colon carcinomas (Figure 4). Moreover, analysis of 
the TCGA expression data generated on CRC showed 
a statistically significant correlation, with the highest 
Pearson index of 0.54, between HMGA1 and SAC genes 
expression, evaluated either by microarray analysis or 
by RNAseq. This correlation strongly increased in liver 
metastases from colon carcinomas (pearson r = 0.72), 
supporting the idea that HMGA1-induced SAC genes 
deregulation may be important during tumour progression.
Altogether, these findings suggest that SAC gene 
overexpression induced by HMGA1 may have a role 
in colorectal cancer progression causing chromosome 
instability. Indeed, although it has also been demonstrated 
that mice carrying conditional Bub1 mutation 
develop severe defects ranging from early lethality to 
tumorigenesis [35], even SAC gene overexpression has 
been reported to impair the spindle assembly checkpoint 
playing a critical role in cancer progression. In fact, MAD2 
overexpression is a common event in many human tumors 
[36, 37], and its overexpression increases nondisjunction 
events and aneuploidy in human fibroblasts and cell lines 
[32]. Moreover, Bub1 and Bub1b expression levels are 
drastically upregulated in gastric cancer associated with 
tumor cell proliferation [23]. Furthermore, colorectal 
cancer patients showing Bub1 and Bub1b upregulation 
have a shorter relapse-free survival with respect to the 
groups showing normal expression of these genes [38].
In conclusion, based on the results presented here, we 
propose a novel mechanism by which HMGA1 overexpression 
contributes to cancer progression activating SAC gene 
expression, thereby inducing chromosomal instability that 
eventually leads to a more advanced cancer status.
MATERIALS AND METHODS
Cell cultures, transfections and plasmids
NIH3T3 and HeLa cell lines were cultured in 
DMEM with 10% FBS, L-glutamine, and antibiotics 
(Invitrogen, Carlsbad, CA). HCT116, SW620 and SW48 
were cultured in McCoy’s with 10% FBS, L-glutamine, 
and antibiotics (Invitrogen). For live-cell imaging, cells 
were cultured in DMEM medium without phenol red, 
supplemented with heat-inactivated FBS (Invitrogen). 
HCT116, SW620, SW48 and NIH3T3 cells were 
transfected using Lipofectamine-Plus reagent (Invitrogen) 
according to manufacturer’s instructions. The pcDNA3.1-
Hmga1b and pCEFL-HA-Hmga1b vectors were 
previously described, respectively [39, 40]. The pLuc-
Bub1b reporter plasmid and pT81-Mad2l1 promoters 
were gifts of Dr. P. Carbon [41] and Dr. CW Lee [42], 
respectively. The Bub1 promoter region was amplified 
by PCR from human genomic DNA using the following 
primers:
lucBub1Fw: 5′-AATTCTCGAGGCTTGAAGCTGT 
TTGACAGG-3′
lucbub1Re: 5′-AATTAAGCTTCACATTCCAAAC 
CCAGGAAG-3′
The forward and reverse primers contain, 
respectively, the recognition sites for the restriction 
enzymes Hind III and XhoI. The amplified fragment 
was cloned into pGL3-Basic Firefly luciferase vector 
(Promega, Fitchburg, WI, USA) at the XhoI and Hind III 
sites upstream the luciferase gene. Human Ttk promoter 
spanning from −524 to +72 relative to the transcription 
start was previously reported [43].
Luciferase assay
Cells were plated in 6 wells plates and after 24 hours 
were transfected with 100 ng of pLuc-Bub1, pLuc-Bub1b, 
pLuc-Mad2l1 or pLuc-Ttk expression vectors together with 
50 ng of pCMV-Renilla plasmid and with different amount 
of pcDNA3.1-Hmga1b expression vector. Luciferase 
and Renilla activities were assessed with the Dual-Light 
Luciferase system (Promega), 48 h after the transfection. 
Luciferase activity was normalized for the Renilla activity. 
All the experiments were performed three times in duplicate 
and the mean ± SD was reported.
Protein extraction, western blotting, 
and antibodies
Cells were lysed in lysis buffer containing 1% NP40, 
1 mM EDTA, 50 mM Tris-HCl (pH 7.5) and 150 mM NaCl, 
supplemented with complete protease inhibitors mixture 
(Roche Branford, CT, USA). Total proteins were separated 
by SDS-polyacrylamide gel electrophoresis and transferred 
to nitrocellulose membranes (Amersham, Rainham, UK) 
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by elettroblotting. Membranes were blocked with 5% 
non-fat dry milk and incubated with antibodies anti-actin 
(sc-1616, Santa Cruz Biotechnology), anti-HMGA1 [44], 
anti-BUBR1 (612503, BD Transduction Laboratories), anti-
TTK (C-19, sc-540 Santa Cruz Biotechnology), anti-MAD2 
(610678, Transduction Laboratories).
Chromatin immunoprecipitation (ChIP) assay
48 hours after transfection, cells have been treated 
with formaldehyde 1%, washed and then lysed isolating 
the nuclei. Then the nuclei have been in turn lysed and 
chromatin has been sonicated. Chromatin has been 
immunoprecipitated using anti-HMGA1 antibody [39] 
or normal rabbit IgG as negative control. After the 
immunoprecipitation, the chromatin has been incubated 
overnight at 65°C with DNAse-free RNAse (Roche). Next 
day, the samples have been incubated 3 hours at 50°C 
with 0, 5% SDS and 0, 5 mg/ml Proteinase K (Roche) 
and after the DNA has been purified with a phenol-
chloroform extraction. For qPCR analysis, 2 μl out of 
150 μl immunoprecipitated DNA was used with primers 
described below. Gapdh promoter amplicon was used as 
negative control in all the experiments. Input DNA was 
used as positive control.
Primers used were:
Bub1-prom -760/-567 Fw 5′-AACCCATCACTTTC 
CAGTGC-3′
Bub1-prom -760/-567 Re 5′-ACATCCCAGATGCTG 
AAACC-3′
Bub1b-prom -740/-550 Fw 5′-GCAAGAAGAAGAC 
CCTGTCTC-3′
Bub1b-prom -740/-550 Re 5′-ATGCTATGGTTCCC 
AAGGTG-3′
Mad2l1-prom -442/-198 Fw 5′-ACCTTATTCCTGT 
CCTGCCC-3′
Mad2l1-prom -442/-198 Re 5′-CCACAGCTTTACA 
GGGTTCG-3′
Ttk-prom -380/-194 Fw 5′-CCGCAAACAGATCAA 
CGAG-3′
Ttk-prom -380/-194 Re 5′-CGTGAGAGCCCTTCTC 
AATC-3′
Gapdh-prom-Fw 5′-CCCAAAGTCCTCCTGTTT 
CA-3′
Gapdh-prom-Re 5′-GTCTTGAGGCCTGAGCTA 
CG-3′
RNA interference, RNA extraction and 
quantitative PCR
RNA interference was obtained by HMGA1-specific 
siRNA sequences (QiagenHs_HMGA1_5 (SI02662023) 
Sense strand GGACAAGGCUAACAUCCCATT and 
Antisense strand UGGGAUGUUAGCCUUGUCCAG] 
using Lipofectamine RNAi MAX (Invitrogen), according 
to manufacturer’s instructions. Qiagen AllStars control 
siRNA (SI03650318) was used as negative control. Cells 
were transduced with 40 nM of siRNA using RNAiMAX 
reagent (Invitrogen) according to the manufacturer’s 
instructions and analyzed after 48 hours. Red fluorescent 
oligonucleotides (Block-it, Invitrogen) were used to 
evaluate transfection efficiency. In our conditions, about 
80% of the cells transfected by siRNA molecules. Total 
RNA was isolated as already described [45]. qPCR 
analysis for Bub1, Bub1b, Mad2l1, Ttk and Hmga1 was 
performed using the Power SYBR Green PCR Master 
Mix (Applied Biosystems) according to manufacters’s 
instructions with following primer sequences:
humanHMGA1-Fw 5′-CAACTCCAGGAAGGAAA 
CCA-3′
humanHMGA1-Re 5′-AGGACTCCTGCGAGAT 
GC-3′
humanBub1-Fw 5′-ACACCATTCCACAAGCTT 
CC-3′
humanBub1-Re 5′-CGCCTGGGTACACTGTTT 
TG-3′
humanBub1b-Fw 5′-TGGAAGAGACTGCACGAC 
AG-3′
humanBub1b-Re 5′-CAGGCTTTCTGGTGCTTA 
GG-3′
humanTtk-Fw 5′-ACCAAGCAGCAATACCTTG 
G-3′
humanTtk-Re 5′-ACTGACAAGCAGGTGGAA 
AG-3′
humanMad2l1-Fw 5′-GACATTTCTGCCACTGTT 
GG-3′
humanMad2l1-Re 5′-AACTGTGGTCCCGACTCT 
TC-3′
humanActin-Fw 5′-CCAACCGCGAGAAGATGA -3′
humanActin-Re 5′-CCAGAGGCGTACAGGGAT 
AG -3′
mouseBub1-Fw 5′- CAAGGACCTTCCTGCTTC 
TG-3′
mouseBub1-Re5′-GACTTGGACCCCTCAATTCC-3′
mouseBub1b-Fw5′-GCCAGATTGCAGATTGCTT 
C-3′
mouseBub1b-Re 5′- GGACAGATGGAACAGGAC 
AG-3′
mouseTtk-Fw 5′-ATATGGCCCCAGAAGCAAT 
C-3′
mouseTtk-Re 5′-CCCCAAGGACCAGACATCA 
C-3′
mouseMad2l1-Fw -5′-AGAAACTGGTGGTGGTC 
ATC-3′
mouseMad2l1-Re 5′-CGAACACCTTCCTCTTTT 
GC-3′
mouseActin-Fw 5′-CTAAGGCCAACCGTGAAA 
AG-3′
mouseActin-Re 5′-ACCAGAGGCATACAGGGA 
CA-3′
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To calculate the relative expression levels we used 
the 2-∆∆CT method [46]. Primers specific for the actin 
were used for normalization of qPCR data.
Statistical analysis
Student’s t test was used to determine the 
significance for all the quantitative experiments. Error 
bars represent the standard deviation (SD) of the 
average. A p-value < 0.05 was considered statistically 
significant.
The χ2 test was used to test the relationship between 
the immunoreactivity of HMGA1 and that of BUBR1 and 
TTK in colon samples. The test indicates how much of 
the association is accounted for linear trend. Statistical 
significance for all the tests was assessed by calculating 
the p-value.
For correlation analysis, TCGA expression data for 
HMGA1, BUB1, BUB1B, MAD2L1 and TTK in colorectal 
cancer were downloaded as z-scores from the cBioPortal 
(http://www.cbioportal.org). Pearson correlation between 
HMGA1 and SAC gene expression was calculated with 
Microsoft Excel. Statistical significance of the observed 
values was assessed on the online portal “Simple Interactive 
Statistical Analysis” (http://www.quantitativeskills.com/
sisa/statistics/correl.htm).
Immunofluorescence
Cells plated on cover-slides in 12 wells plates were 
fixed in 4% formaldehyde in PBS and permeabilized in 
a solution of 0.25% Triton X-100 in PBS. Anti β-tubulin 
antibody conjugated to CY3 (Sigma) was used to identify 
mitotic spindle in mitotic cells, and DAPI staining was 
used to identify chromosomes. Cells were observed with a 
fluorescent microscope (Zeiss, magnification 63X or 100X).
Live-cell imaging
Cells were seeded in slides 8-well (80826, 
ibiTreat, Ibidi) and observed under an Eclipse Ti inverted 
microscope (Nikon) using a 40x objective (Nikon). 
During the observation, cells were kept in a microscope 
stage incubator (Basic WJ, Okolab) at 37°C and 5% CO2. 
DIC images were acquired over a 24 hr period by using 
a DS-Qi1Mc camera. Image and video processing were 
performed with NIS-Elements AR 3.22.
Immunohistochemistry
Immunohistochemical analysis of paraffin-
embedded tissues was performed with antibodies against 
HMGA1, BUBR1 and TTK, using polyclonal antibodies 
above mentioned, as previously described [47]. No 
staining was observed when normal colon samples were 
stained without the primary antibodies (data not shown).
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